Arquer Diagnostics Appoints Nadia Whittley as CEO
December 1, 2016 – Pharmaceutical –
Sunderland, UK, 1st December 2016: Arquer Diagnostics Ltd, a
diagnostic company which has developed a high sensitivity, high
specificity, ELISA-based urine test for cancer, today announced that it
has appointed Nadia Whittley as CEO with immediate effect. With
significant experience in strategy, sales and marketing, organisational
effectiveness, M&A and fundraising in the small and mid-cap sectors,
Nadiaís focus at Arquer will be to execute the commercial launch of the
Companyís MCM5-ELISA diagnostic test, and expansion of the technology
into a wider range of cancers.
With over 25 yearsí experience in
the life science sector, Nadia Whittley has an outstanding leadership
record of growing revenues and motivating teams spanning several
therapeutic areas and across different geographies, including EMEA, Asia
Pacific and North America. Most recently Nadia was Partner and Managing
Director, Europe, of Tefen Management Consulting, where she was
responsible for the design and implementation of a 5-year strategic plan
and development of the Life Science Business Unit in EMEA. Previously
Nadia was CEO at Alium Medical Ltd, Managing Director Medical Devices
EAME at Allergan Inc., Marketing Director EMEA in Interventional
Cardiology at Boston Scientific International, and a non-executive Board
member at Peptonic Medical AB.
Commenting on the appointment, Dr Sandy Primrose, Chairman Arquer, said: ‘I would like to welcome Nadia and am delighted that we have someone
with her commercial background as our new CEO. Her experience of
successfully launching new technologies across multiple regions and her
knowledge of the sector make her a real asset to the business,
particularly as we move forward to commercialise our MCM5-ELISA
diagnostic test. I would also like to take this opportunity to thank
outgoing CEO, Dr Ian Campbell, for his work in the development of Arquer
to this exiting stage and to wish him well in his new role.’
Nadia Whittley commented: ‘In
Arquer, and the introduction of the companyís MCM5-ELISA diagnostic
test, I see a real opportunity to provide a novel technology that will
both improve patient outcomes and help to reduce healthcare costs. The
MCM5-ELISA is expected to significantly reduce the number of patients
undergoing invasive and costly techniques such as cystoscopy and biopsy,
because it offers highly accurate diagnostic results from small amounts
of body fluid. I am delighted to have joined Arquer at such an exciting
time for the company.’
Arquerís diagnostic test, the
MCM5-ELISA, detects the presence of minichromosome maintenance (MCM)
protein, a marker for the presence of dividing cancer cells, in urine,
to accurately diagnose both bladder and prostate cancer. MCM proteins
are excellent biomarkers, being directly involved in cell replication,
and are shed into urine by both prostate and bladder tumours.
For more information, please visit www.arquerdx.com/
